Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement
Osteoarthritis

About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring Tranexamic acid, 6-Aminocaproic Acid, Arthroplasty, Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Antifibrinolytic Agents, Fibrin Modulating Agents, Pharmacologic Actions, Coagulants, Therapeutic Uses
Eligibility Criteria
Inclusion Criteria:
- Persons aged 18 - 90 years who are scheduled to undergo a unilateral total knee replacement surgery
Exclusion Criteria:
- Non-English speaking individuals
- Individuals with a history of deep vein thrombosis or pulmonary embolism within one year
- Individuals with a history of coagulopathy
- Heart stent within one year
- Pre-operative autologous blood donation
- Unwilling or unable to take Coumadin for deep vein thrombosis (DVT) prophylaxis
- Received nonsteroidal anti-inflammatory drug (NSAID) or platelet antiaggregant treatment within five days prior to surgery
- Pre-operative creatinine greater than 1.5mg/dL
Sites / Locations
- Miller Orthopedic Specialists
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Tranexamic acid (TXA)
ε-Aminocaproic Acid (EACA)
1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.
7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.